Description: Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York.Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
420 Lexington Avenue
New York,
NY
10170
United States
Phone:
347-627-0058
Officers
| Name | Title |
|---|---|
| Mr. Leonard L. Mazur | Chairman, CEO & President |
| Mr. Jaime Bartushak | CFO & Treasurer |
| Dr. Myron S. Czuczman M.D. | Chief Medical Officer |
| Mr. Myron Z. Holubiak | Secretary & Director |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Life Sciences Tools & Services |
| GIC Sub-Industry: | Life Sciences Tools & Services |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.5515 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2022-12-08 |
| Fiscal Year End: | September |
| Full Time Employees: | 0 |